Our biomarker-driven approach will
redefine cancer treatment.
- Company
- Therapeutic Areas
- Programs
- Clinical Trials
- Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera to Present at the H.C. Wainwright Global Investment Conference
-
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
-
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
-
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
-
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Investors
- Clinical Trials
- Programs
- Therapeutic Areas
